Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
This resource was co-financed by the Next Generation EU [DM 1557 11.10.2022]
L.ShimabukuroR
Furthermore, NCT03810872 explores the utility of intermittent afatinib in patients with EGFR, HER2, or HER3 mutations to mitigate resistance via on-off EGFR/HER blockade
The volume of distribution (Vd) can be calculated by dividing the administered dose by the phenobarbital level
Weeks 13-24: Optimization Phase By month four, most users reach stable dosing with adapted tolerability
US$ 27.20
US$ 22.89
US$ 25.53
US$ 25.28
US$ 22.31
US$ 22.75
US$ 25.51
US$ 23.15
